Oncology

Overview

The Oncology research area is composed by nine groups addressing the principal unsolved issues in cancer. Their research covers fields such as child and adolescent cancer, melanoma, Gynecology, Urology, cancer stem cells and the molecular mechanisms of the tumor pathologies.

There are also three groups from the CIBBIM-Nanomedicine. These groups study the use of nanotechnology in biomedical applications to improve therapeutic strategies and diagnostics.

Publications

125

total

725.353

impact factor

5.803

average impact factor

Group Leader: Simó Schwartz Navarro

team

zoom

download

The group on Drug Delivery and Targeting seeks on the one hand, the identification of new disease biomarkers and therapeutic targets, with special focus on cancer molecular pathways and in the physiopathology of low prevalent diseases; and on the other hand, the development of new drug delivery strategies as applied nanomedicine, with a particular interest into new targeting approaches for clinical applications.

Several in vitro and in vivo cancer models have been generated by the group for preclinical testing of nanomedicines, including the generation of specific bioluminescent cancer stem cell models. Further, we have generated new polymer nanoconjugates against metastatic cancer showing no toxicity profiles, high in vivo efficacy and industrial transferability. A total of 14 patents have been issued by our group. Three patents from the group are either issued or advanced to National Phases.

13

total

74^.454

impact factor

5^.727

average impact factor

SELECTED ARTICLES

Méndez O, Peg V, Salvans C, Pujals M, Fernández Y, Abasolo I, Pérez J, Matres A, Valeri M, Gregori J, Villarreal L, Schwartz S Jr, Ramon Y Cajal S, Tabernero J, Cortés J, Arribas J, Villanueva J. Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer.
Clin Cancer Res. 2018 Dec 15;24(24):6367-6382. DOI: 10.1158/1078-0432.CCR-18-0517
IF: 10,199
Rafael D, Gener P, Andrade F, Seras-Franzoso J, Montero S, Fernández Y, Arango D, Sayós J, Abasolo I, Schwartz S Jr*, Videira M*. AKT2 siRNA delivery with amphiphilic-based polymeric micelles show efficacy against Cancer Stem Cells. (*co-corresponding authors).
Drug Delivery, 2018 Nov;25(1):961-972.
DOI: 10.1080/10717544.2018.1461276
IF: 6,402
Gener P, Seras-Franzoso J, González-Callejo P, Andrade F, Rafael D, Martínez F, Montero S, Arango D, Sayós J, Abasolo I, Schwartz S Jr.
Dynamism, Sensitivity, and Consequences of Mesenchymal and Stem-Like Phenotype of Cancer Cells.
Stem Cells Int., 2018 Oct 10;2018:4516454 (review)
DOI: 10.1155/2018/4516454
IF: 3,989
Rafael D, Martínez F, Andrade F, Seras-Franzoso J, Gener P, Sayós J, Arango D, Abasolo I, Schwartz S Jr.
Efficient EFGR mediated siRNA delivery to Breast Cancer Cells by Cetuximab Functionalized Pluronic® F127/Gelatin.
Chem. Eng. J., Volume 340, 15 May 2018, Pages 81-93
doi.org/10.1016/j.cej.2017.12.114
IF: 6,735
Rocas P, Fernandez Y, Garcia-Aranda N, Foradada L, Calvo P, Aviles P, Guillen MJ, Schwartz S Jr, Rocas J, Albericio F, Abasolo I
Improved Pharmacokinetic Profile of Lipophilic Anti-Cancer Drugs Using alphanubeta3-targeted Polyurethane-Polyurea Nanoparticles.
Nanomedicine. 2018 Feb;14(2):257-267. doi: 10.1016/j.nano.2017.10.009.
DOI: 10.1016/j.nano.2017.10.009
IF: 6,5

View all publications

Oncology

Overview

Publications

Group Leader: Simó Schwartz Navarro

Research Areas